Pharsight

Drugs that contain Simeprevir Sodium

1. Olysio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7671032 JANSSEN PRODS HCV NS-3 serine protease inhibitors
May, 2025

(11 months from now)

US8754106 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8741926 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US9040562 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8349869 JANSSEN PRODS Macrocylic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US9856265 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US8148399 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Sep, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9353103 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

US9623022 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-717) Oct 05, 2018
New Indication(I-697) Nov 05, 2017
New Dosing Schedule(D-151) Oct 05, 2018
M(M-179) May 20, 2019
New Chemical Entity Exclusivity(NCE) Nov 22, 2018
M(M-171) Feb 26, 2019

NCE-1 date: 22 November, 2017

Market Authorisation Date: 22 November, 2013

Treatment: Method of treating hepatitis c

Dosage: CAPSULE;ORAL

More Information on Dosage

OLYSIO family patents

Family Patents